文献速递肾小球疾病慢性肾脏病

儿童狼疮患者肾素-血管紧张素-醛固酮系统抑制剂的使用与糖皮质激素停药时间

Use of renin angiotensin aldosterone system inhibitors in children with lupus and time to glucocorticoid discontinuation.
PubMed 文献 · Kidney Int · 2022-05-23

本研究基于Truven MarketScan Medicaid和商业数据库(2013-2018年)的回顾性队列,纳入592例狼疮肾炎患儿和1407例非肾脏狼疮患儿,分别有67%和15%曾使用RAAS抑制剂。在158例新发肾炎病例中,诊断后180天内启动RAAS抑制剂与糖皮质激素停药更快显著相关(校正亚分布风险比1.81,95%CI 1.09-3.00)。作者认为早期启动RAAS抑制剂可能对新诊断狼疮肾炎患儿有益。

要点

  • 狼疮肾炎患儿RAAS抑制剂使用率67%,非肾脏狼疮患儿15%。
  • 新发肾炎病例中,180天内启动RAAS抑制剂与糖皮质激素停药更快相关(校正亚分布风险比1.81,95%CI 1.09-3.00)。
  • 早期启动RAAS抑制剂可能对新诊断狼疮肾炎患儿有益,不仅限于诱导治疗后难治性蛋白尿者。

核心结论

  • 在新发狼疮肾炎患儿中,诊断后180天内启动RAAS抑制剂与糖皮质激素停药更快显著相关(校正亚分布风险比1.81,95%CI 1.09-3.00)。
  • 早期启动RAAS抑制剂可能对新诊断狼疮肾炎患儿有益,不仅限于诱导治疗后难治性蛋白尿者。

研究设计与样本

  • 回顾性队列研究,使用Truven MarketScan Medicaid和商业数据库(2013-2018年),纳入5-18岁系统性红斑狼疮和/或狼疮肾炎患儿。
  • 采用竞争风险 hazard 模型和逆概率治疗加权,以肾衰竭为竞争事件,估计RAAS抑制剂启动与糖皮质激素停药时间的关联。

主要发现

  • 592例肾炎患儿中67%曾使用RAAS抑制剂,1407例非肾脏狼疮患儿中15%曾使用。
  • 323例新发使用者中,肾炎患儿RAAS抑制剂使用中位持续时间14个月,无肾炎患儿9个月。
  • 无论有无肾炎,Medicaid参保与RAAS抑制剂使用可能性更高独立相关。
  • 158例新发肾炎病例中,早期启动RAAS抑制剂与糖皮质激素停药更快显著相关(校正亚分布风险比1.81,95%CI 1.09-3.00)。

临床怎么用

  • 作者认为早期启动RAAS抑制剂可能对新诊断狼疮肾炎患儿有益,不仅限于诱导治疗后难治性蛋白尿者。
  • 作者提出可利用整合健康系统数据确认这些发现并优化儿童狼疮的辅助治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

There is little data to inform use of renin angiotensin aldosterone system (RAAS) inhibitors in pediatric patients with systemic lupus erythematosus (SLE). Here, we sought to characterize RAAS inhibitor use in pediatric SLE and determine whether early RAAS inhibitor initiation among children with incident lupus nephritis is associated with decreased duration of chronic glucocorticoid exposure. A retrospective cohort study was performed of children (ages 5-18) with SLE and/or lupus nephritis in the Truven MarketScan™ Medicaid and Commercial databases (2013-2018) and estimated RAAS inhibitor use. Among incident nephritis cases, we used competing risk hazard models with inverse probability of treatment weighting to estimate the association between RAAS inhibitor initiation less than 180 days after diagnosis and time to glucocorticoid discontinuation with kidney failure as a competing event. Among 592 children with nephritis and 1407 children with non-kidney SLE, 67% and 15% ever received RAAS inhibitors, respectively. Median duration of RAAS inhibitor use among 323 incident users was 14 and 9 months in children with and without nephritis, respectively. Medicaid enrollment was independently associated with greater likelihood of RAAS inhibitor use, irrespective of nephritis. Among 158 incident nephritis cases, early RAAS inhibitor initiation was significantly associated with a faster rate of glucocorticoid discontinuation (adjusted sub-distribution hazard ratio 1.81, 95% confidence interval [1.09 - 3.00]). Thus, early initiation of RAAS inhibitors may have a role in children newly diagnosed with lupus nephritis; not only those with refractory proteinuria after induction therapy. Hence, integrated health systems data could be leveraged to confirm these findings and optimize adjunctive therapies in pediatric lupus.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Chang JC, Weiss PF, Xiao R, et al. Use of renin angiotensin aldosterone system inhibitors in children with lupus and time to glucocorticoid discontinuation. Kidney Int. 2022. PMID: 35618096. doi:10.1016/j.kint.2022.04.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。